Status:
COMPLETED
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
University of Lausanne Hospitals
University Hospital, Lille
Conditions:
Invasive Fungal Disease
Chronic Disseminated Candidiasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
Detailed Description
Chronic disseminated candidiasis, often referred to as hepatosplenic candidiasis (HSC), is an infection due to Candida spp. that mainly involves the liver and spleen. HSC occurs mostly in patients wit...
Eligibility Criteria
Inclusion
- Patients' inclusion criteria:
- Adults aged ≥18 years-old
- Hospitalized for hematological malignancy or hematopoietic stem cell transplantation
- Recent (\>2months), prolonged (\>10 days), profound (\>100 PMN/mm3), feverish neutropenia
- Suspected hepatosplenic candidiasis (typical small nodular lesions on abdominal RMI or CT)
- Patients' exclusion criteria:
- \- hepatosplenic lesions of other proven origin
- Patients' non-inclusion criteria:
- Life expectancy \>3 months
- Pregnancy
- HIV infection
- Hepatic biopsy within 3 weeks before 18F-FDG PET scan
Exclusion
Key Trial Info
Start Date :
November 19 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01916057
Start Date
November 19 2013
End Date
February 28 2018
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants Malades,
Paris, France, 75015